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We welcome debate and are pleased to offer a brief reply.
We accept that the timing and dosing of perioperative
-blockade for vascular surgery may be important, as may be the
choice of patients. We emphasize the following four points:
1. The POBBLE trial had the advantage, over previous published
trials, of being a double-blind placebo-controlled trial. Trials
with tight control of heart rate cannot, of course, be double-
blind.
2. The POBBLE trial was pragmatic and designed to accord with
British clinical practice. Recruitment would have been even
more difficult if -blockade had to be started long before the
planned operation.
3. Clinical guidelines need to be simple if they are to be valuable
and adhered to. Therefore, the recommendation of a fixed dose
of -blocker (with a half dose for those 55 kg) would have
been more useful than a complex sliding scale.
4. Two-year survival was a secondary outcome of the POBBLE
trial and will be reported toward the end of 2006.
From the Holter monitor traces, we have detailed information
about heart rates in the first 72 hours after surgery, and we would
be pleased to share this information.
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